Login/Sign Up
₹14999
(Inclusive of all Taxes)
Get Free delivery (₹99) with
Admarib 150 mg Tablet 60's is an oral prescription medication used to treat certain advanced cancers, including ovarian, breast, prostate, and pancreatic cancers. It is specifically designed for cancers that have specific abnormal genes, such as the BRCA gene. This targeted therapy helps slow down or stop the growth of cancer cells in the body.
You will typically take Admarib 150 mg Tablet 60's twice a day, with or without food, as directed by your doctor. It is important to take this medication consistently at the same times every day to maintain a steady level of the medicine in your body. To support your body during treatment, focus on staying hydrated, eating small, frequent meals, and getting adequate rest.
While taking Admarib 150 mg Tablet 60's, you may experience common side effects such as nausea, tiredness, and low red blood cell counts. However, if you develop serious symptoms like severe shortness of breath, a sudden cough, or an unexplained fever, you must contact your doctor immediately.
Before starting Admarib 150 mg Tablet 60's, talk to your doctor if you have a history of kidney problems or lung conditions. Do not take this if you are pregnant or breastfeeding, as it can cause serious harm to a developing baby.
This medication can interact with other drugs and certain foods like grapefruit, which can alter how the medicine works in your body. It is also important to talk to your doctor or pharmacist if you are elderly or have other chronic health conditions to ensure Admarib 150 mg Tablet 60's is safe for you.
Admarib 150 mg Tablet 60's is used in the treatment of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. The detailed uses of Admarib 150 mg Tablet 60's are as follows:
Admarib 150 mg Tablet 60's helps manage certain advanced cancers by targeting specific cancer cells and interfering with their ability to repair themselves.
The following are the benefits of this medication:
Caution
Avoid alcohol consumption while on treatment with Admarib 150 mg Tablet 60's.
Unsafe
Admarib 150 mg Tablet 60's should not be used during pregnancy because it can harm your fetus (newborn baby). Both women of childbearing potential and men must use an effective contraception method while taking Admarib 150 mg Tablet 60's and at least for six months later treatment. Your doctor will weigh the benefits and risks before prescribing this medicine.
Unsafe
Do not breastfeed during this treatment because the medicine may pass into your milk. Doctors normally advise against breastfeeding throughout this treatment and for one month after the final medication is taken.
Caution
Admarib 150 mg Tablet 60's may affect your reactions and your ability to drive. Do not drive and/or operate machines that require your alertness.
Caution
In patients with mild or moderate liver impairment, there is no need to alter the initial dose. There is no information available on patients with severe liver impairment.
Caution
In patients with mild or moderate kidney impairment, there is no need to alter the initial dose. There is no information available on patients with severe kidney impairment.
Caution
The safety and effectiveness of Admarib 150 mg Tablet 60's in pediatric patients have not been established.
Consult your doctor
Please consult your doctor before receiving Admarib 150 mg Tablet 60's if you have pre-existing heart problems. Your doctor will prescribe Admarib 150 mg Tablet 60's if the benefits outweigh the risks.
Consult your doctor
Please consult a doctor before administering Admarib 150 mg Tablet 60's to geriatric patients. Your doctor will prescribe Admarib 150 mg Tablet 60's if the benefits outweigh the risks.
Have a query?
The time required for Admarib 150 mg Tablet 60's to start to work: Admarib 150 mg Tablet 60's ideally shows its action within few hours after administration. The time for which the effects of Admarib 150 mg Tablet 60's last: The duration of action for Admarib 150 mg Tablet 60's is unknown.
Login/Sign Up
Login/Sign Up
Disclaimer
